Drugs / Nivolumab-relatlimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03645928 | May 2019 → Feb 2026 | head and neck squamous cell carcinoma, metastatic melanoma, non-small cell lung carcinoma | Iovance Biotherapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nivolumab-relatlimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03645928 ↗ |
| Known as | Opdualag | “Opdualag” NCT03645928 ↗ |
| Modality | Monoclonal antibody | “Monoclonal antibody (nivolumab) and monoclonal antibody (relatlimab)” NCT03645928 ↗ |